Tempus AI Shares Rise 4.71% on Analyst Upgrades Despite 404th-Ranked 350M Trading Volume

Market Snapshot

On February 6, 2026, Tempus AI (TEM) closed with a 4.71% increase in its stock price, marking a notable rebound despite a 23.51% decline in trading volume compared to the previous day. The company’s shares saw a total trading volume of $0.35 billion, ranking it 404th in market activity for the day. The drop in volume, coupled with the positive price movement, suggests a consolidation phase following recent analyst activity and market positioning. Investors appeared to balance reduced liquidity with renewed confidence, as evidenced by the stock’s upward trajectory.

Key Drivers

The surge in Tempus AI’s stock price on February 6 was primarily fueled by a strong consensus among analysts, with 11 out of 22 firms maintaining or upgrading their “Buy” ratings in the preceding weeks. Notably, Canaccord Genuity and Morgan Stanley reaffirmed their “Buy” positions with price targets of $110 and $85, respectively, while BTIG and Needham raised their targets to $105 and $100. These elevated price points, significantly above the stock’s closing price, signaled robust confidence in the company’s growth potential and technical advancements in its AI-driven healthcare platform.

A critical factor underlying the positive sentiment was the recent maintenance of “Buy” ratings by major institutions such as H.C. Wainwright and Piper Sandler, which have historically influenced institutional investment flows. For instance, H.C. Wainwright’s $98 price target, which implies an 86.88% upside from its 2025-09-12 recommendation, underscored long-term optimism about Tempus’ ability to scale its oncology data analytics services. Similarly, Piper Sandler’s repeated “Hold” ratings with $105 price targets—maintained since October 2025—highlighted a stable, albeit cautious, institutional stance.

The ex-dividend date of February 4 further contributed to short-term volatility. While the dividend itself (unspecified in the data) may not have directly impacted February 6’s price, the timing coincided with a strategic repositioning by investors. Traders likely adjusted portfolios ahead of the ex-dividend date, which may have amplified the stock’s responsiveness to analyst upgrades. This interplay between dividend-driven liquidity shifts and analyst-driven sentiment created a dynamic environment for the stock.

Lastly, the divergence in analyst ratings—ranging from “Buy” to “Hold” and even rare “Downgrade” actions—reflected a nuanced market view. Firms like TD Cowen and JPMorgan maintained “Hold” ratings, suggesting tempered expectations, while Morgan Stanley’s new coverage with a $85 price target added fresh momentum. The absence of any “Sell” ratings in the dataset reinforced an overall bullish bias, even as some analysts, such as Stifel and Guggenheim, maintained lower price targets ($65–$75), which could indicate sector-wide caution against overvaluation risks.

In summary, the 4.71% gain was driven by a combination of analyst-driven optimism, strategic dividend timing, and a lack of bearish sentiment. The stock’s performance underscores the market’s focus on Tempus AI’s long-term AI healthcare integration potential, despite near-term liquidity constraints.